Product Images Glipizide And Metformin Hcl

glipiZIDE/metFORMIN HCI is a tablet containing 2.5mg/250 mg, and the quantity of the tablets is 180. The product's NDC # is 70518-2196-00, and the manufacturer is Heritage based in East Brunswick, NJ 08816. The product's lot number is not available, and the expiry date is also missing. The medication needs to be kept away from the reach of children. The product should be stored at a temperature of 20-26°C (63-77°F), with permitted excursions to 15-30°C (59-86°F) as per USP. The package insert provides the directions for use. The product was repackaged by RemedyRepack Inc., based in Indiana, PA 15701.*

This text presents data on the effect of Metformin Dose® on renal clearance in different groups of subjects. The study included healthy, nondiabetic adults, adults with type 2 diabetes, elderly healthy nondiabetic adults, and renal-impaired adults. The data shows the number of subjects, the peak plasma concentration, time to peak plasma concentration, and renal clearance values for each group. The results suggest that Metformin Dose® may have different effects on renal clearance depending on the subject group. However, the exact clinical implications of these findings are not clear.*

This is a table of different types of tablets including Glipizide 5mg, Metformin 500mg, Glipizide and Metformin HCI 2.5mg/250mg tablets, and Glipizide and Metformin HCI 2.5mg/500mg tablets. The table shows information on Mean Final Dose, Hemoglobin A_(%), % Patients with Final HbA,_<7%, and Fasting Plasma Glucose (mg/dL). There are also differences from Glipizide and Metformin, and the results show adjustments mean changes from baseline. The p-value is less than 0.001.*

This is a comparison of the effectiveness of Glipizide and Metformin HCI tablets (5mg/500mg) to Glipizide tablets (5mg) and Metformin tablets (500mg) on diabetic patients. The study was conducted on a total of 80 participants for HbA1c levels and 81 participants for fasting plasma glucose levels. The results indicate that the Glipizide and Metformin HCI tablets combination achieved a lower final adjusted mean HbA1c level than Glipizide or Metformin alone, and a greater decrease in fasting plasma glucose levels than either drug alone. The percentage of patients with the final HbA1c level below 7% was also higher in the Glipizide and Metformin HCI group. The study suggests that the combination of Glipizide and Metformin HCI may be more effective in managing diabetes than either drug alone.*

The text provides a table with the number and percentages of patients who experienced different adverse events when treated with different combinations of Glipizide and Metformin HCI tablets. The adverse events listed include upper respiratory infection, diarrhea, dizziness, hypertension, and nausea/vomiting. The table provides information on the number of patients and percentages who experienced each adverse event for each tablet combination.*

This appears to be a table showing the number of patients and the percentage of patients experiencing adverse events while taking Glipizide 5 mg, Metformin 500 mg, and Glipizide and Metformin HCI tablets. The adverse events listed include diarrhea, headache, upper respiratory infection, musculoskeletal pain, nausea/vomiting, abdominal pain, and UTI. The dose of Glipizide was fixed at 30 mg daily, while the doses of Metformin and Glipizide and Metformin HCI Tablets were titrated.*